Year: 2016

Rights issue

  • 09:28

Immunicum announces fully underwritten rights issue of about SEK 111 million to extend phase II-trial with new clinics… Read more

Company analysis

  • 10:33

Redeye releases a company analys of Immunicum. Read it here: Redeye – analysis 160401

New Investors Relations Firm

  • 18:20

Immunicum has engaged The Blueshirt Group to assist Immunicum in developing its communication and investor outreach program with… Read more

Mereca update

  • 13:33

Immunicum AB (publ) today reports a significantly improved vaccine cell handling and gives a status update from the… Read more